Hypertrophic cardiomyopathy: Quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging

Radiology

Volumn 258, Issue 1, 2011, Pages 128-133

  Harrigan, Caitlin J ^a   Peters, Dana C ^a   Gibson, C Michael ^a   Maron, Barry J ^b   Manning, Warren J ^a   Maron, Martin S ^c   Appelbaum, Evan ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; ARTICLE; CARDIOVASCULAR SYSTEM; CASE REPORT; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; HEART FAILURE; HEART MUSCLE; HEMODYNAMIC PARAMETERS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; REPRODUCIBILITY;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES;

EID: 78650613425     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10090526     Document Type: Article

References (23)

1. Bondarenko O, Beek AM, Hofman MB, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson 2005;5(2):481-485.
2. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;500(19):1992-2002.
3. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;50(12):2156-2164.
4. Moon JC, Mogensen J, Elliott PM, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart 2005;51(8):1036-1040.
5. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003;51(9):1561-1567.
6. Schmidt A, Azevedo CF, Cheng A, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 2007;515(15):2006- 2014.
7. Yan A T, Shayne AJ, Brown KA, et al. Characterization of the peri-infarct zone by contrastenhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 2006;514(1):32-39.
8. Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 2000;56(6):1985-1991.
9. Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. Circulation 2002;506(18):2322-2327.
10. Amado LC, Gerber BL, Gupta SN, et al. Accurate and objective infarct sizing by contrastenhanced magnetic resonance imaging in a canine myocardial infarction model. J Am Coll Cardiol 2004;54(12):2383-2389.
11. Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;58(10):1977-1985.
12. Maron MS, Appelbaum E, Harrigan CJ, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008;5(3):184-191.
13. van der Geest RJ, Buller VG, Jansen E, et al. Comparison between manual and semiautomated analysis of left ventricular volume parameters from short-axis MR images. J Comput Assist Tomogr 1997;51(5):756-765.
14. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;5(8476):307-310.
15. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 2001;58(3):275-279.
16. Babu-Narayan SV, Kilner P J, Li W, et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of fallot and its relationship to adverse markers of clinical outcome. Circulation 2006;513(3):405-413.
17. Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51(25):2414-2421.
18. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. Heart 2008;54(6):730-736.
19. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51(14):1369-1374.
20. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;543(20):1445-1453.
21. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of nonischaemic cardiomyopathies. Eur Heart J 2005;56(15):1461-1474.
22. Jackson E, Bellenger N, Seddon M, Harden S, Peebles C. Ischaemic and non-ischaemic cardiomyopathies: cardiac MRI appearances with delayed enhancement. Clin Radiol 2007;52(5):395-403.
23. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;53(12):2260-2264.